Reata Pharmaceuticals Inc (NASDAQ:RETA) Insider Sells $340,000.00 in Stock

Reata Pharmaceuticals Inc (NASDAQ:RETA) insider Elaine Castellanos sold 2,000 shares of the business’s stock in a transaction on Friday, October 18th. The stock was sold at an average price of $170.00, for a total value of $340,000.00. Following the sale, the insider now owns 13,933 shares of the company’s stock, valued at approximately $2,368,610. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Elaine Castellanos also recently made the following trade(s):

  • On Monday, October 14th, Elaine Castellanos sold 3,000 shares of Reata Pharmaceuticals stock. The stock was sold at an average price of $105.00, for a total value of $315,000.00.
  • On Friday, September 6th, Elaine Castellanos sold 2,000 shares of Reata Pharmaceuticals stock. The stock was sold at an average price of $85.00, for a total value of $170,000.00.

NASDAQ RETA opened at $180.18 on Wednesday. The stock has a 50-day simple moving average of $100.67 and a 200 day simple moving average of $88.98. The company has a market capitalization of $5.57 billion, a PE ratio of -62.78 and a beta of 2.40. Reata Pharmaceuticals Inc has a 12 month low of $47.50 and a 12 month high of $189.39.

Reata Pharmaceuticals (NASDAQ:RETA) last released its quarterly earnings data on Thursday, August 8th. The company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.02). The company had revenue of $7.83 million during the quarter, compared to the consensus estimate of $7.76 million. Reata Pharmaceuticals had a negative net margin of 410.38% and a negative return on equity of 3,282.73%. On average, equities research analysts predict that Reata Pharmaceuticals Inc will post -5.33 EPS for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Resources Investment Advisors LLC. acquired a new position in Reata Pharmaceuticals in the second quarter valued at about $25,000. Meadow Creek Investment Management LLC grew its stake in Reata Pharmaceuticals by 71.4% in the second quarter. Meadow Creek Investment Management LLC now owns 336 shares of the company’s stock valued at $32,000 after acquiring an additional 140 shares during the period. Glen Harbor Capital Management LLC grew its stake in Reata Pharmaceuticals by 71.4% in the second quarter. Glen Harbor Capital Management LLC now owns 408 shares of the company’s stock valued at $39,000 after acquiring an additional 170 shares during the period. Optimum Investment Advisors acquired a new position in Reata Pharmaceuticals in the second quarter valued at about $76,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Reata Pharmaceuticals by 25.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,240 shares of the company’s stock valued at $100,000 after acquiring an additional 249 shares during the period. Institutional investors and hedge funds own 58.51% of the company’s stock.

A number of research firms have recently weighed in on RETA. Robert W. Baird restated an “outperform” rating and set a $162.00 target price (up previously from $105.00) on shares of Reata Pharmaceuticals in a research report on Tuesday, October 15th. Cantor Fitzgerald boosted their target price on Reata Pharmaceuticals from $125.00 to $180.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 15th. Leerink Swann set a $230.00 target price on Reata Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, October 15th. BidaskClub upgraded Reata Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, October 17th. Finally, ValuEngine downgraded Reata Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, October 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. Reata Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $205.75.

About Reata Pharmaceuticals

Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases.

Read More: What is Call Option Volume?

Insider Buying and Selling by Quarter for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.